Département de Virologie, Unité d'épidémiologie et physiopathologie des virus oncogènes, Institut Pasteur Paris, France ; CNRS, URA3015 Paris, France.
Front Microbiol. 2012 Nov 15;3:388. doi: 10.3389/fmicb.2012.00388. eCollection 2012.
The human T-cell leukemia virus type 1 (HTLV-1), identified as the first human oncogenic retrovirus 30 years ago, is not an ubiquitous virus. HTLV-1 is present throughout the world, with clusters of high endemicity located often nearby areas where the virus is nearly absent. The main HTLV-1 highly endemic regions are the Southwestern part of Japan, sub-Saharan Africa and South America, the Caribbean area, and foci in Middle East and Australo-Melanesia. The origin of this puzzling geographical or rather ethnic repartition is probably linked to a founder effect in some groups with the persistence of a high viral transmission rate. Despite different socio-economic and cultural environments, the HTLV-1 prevalence increases gradually with age, especially among women in all highly endemic areas. The three modes of HTLV-1 transmission are mother to child, sexual transmission, and transmission with contaminated blood products. Twenty years ago, de Thé and Bomford estimated the total number of HTLV-1 carriers to be 10-20 millions people. At that time, large regions had not been investigated, few population-based studies were available and the assays used for HTLV-1 serology were not enough specific. Despite the fact that there is still a lot of data lacking in large areas of the world and that most of the HTLV-1 studies concern only blood donors, pregnant women, or different selected patients or high-risk groups, we shall try based on the most recent data, to revisit the world distribution and the estimates of the number of HTLV-1 infected persons. Our best estimates range from 5-10 millions HTLV-1 infected individuals. However, these results were based on only approximately 1.5 billion of individuals originating from known HTLV-1 endemic areas with reliable available epidemiological data. Correct estimates in other highly populated regions, such as China, India, the Maghreb, and East Africa, is currently not possible, thus, the current number of HTLV-1 carriers is very probably much higher.
人类 T 细胞白血病病毒 1 型(HTLV-1)在 30 年前被确定为首个人类致癌逆转录病毒,它并不是一种普遍存在的病毒。HTLV-1 遍布全球,高地方性流行区通常位于病毒几乎不存在的附近地区。主要的 HTLV-1 高地方性流行区包括日本西南部、撒哈拉以南非洲和南美洲、加勒比地区以及中东和澳大拉西亚-美拉尼西亚的一些焦点地区。这种令人困惑的地理或种族分布的起源可能与某些群体中的创始效应有关,这些群体中存在着高病毒传播率。尽管存在不同的社会经济和文化环境,但在所有高地方性流行区,HTLV-1 的流行率随着年龄的增长而逐渐增加,尤其是女性。HTLV-1 的三种传播途径是母婴传播、性传播和通过受污染的血液制品传播。二十年前,de Thé 和 Bomford 估计 HTLV-1 携带者的总数为 1000 万至 2000 万人。当时,许多地区尚未进行调查,可用于 HTLV-1 血清学的人群研究较少,且用于 HTLV-1 血清学检测的检测方法特异性不足。尽管目前在世界上的许多地区仍缺乏大量数据,而且大多数 HTLV-1 研究仅涉及献血者、孕妇或不同的选定患者或高危人群,但我们将尝试根据最新数据,重新审视 HTLV-1 的全球分布和感染人数的估计。我们的最佳估计值范围在 500 万至 1000 万 HTLV-1 感染者之间。然而,这些结果仅基于来自已知 HTLV-1 地方性流行区的约 15 亿人,这些地区具有可靠的可用流行病学数据。在其他人口众多的地区,如中国、印度、马格里布和东非,目前无法进行正确的估计,因此,目前的 HTLV-1 携带者数量很可能更高。